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1  | INTRODUC TION
Clonal mast cell disorders (cMCD) comprise systemic mastocyto‐
sis (SM) and monoclonal mast cell activation syndrome (MMAS).1,2 
Common to these two conditions is the presence of mast cell (MC) 
clonality, as reflected in a mutation in codon 816 of KIT and/or 
occurrence of immunophenotypically aberrant MCs expressing 
CD25.3 In patients with MMAS, the WHO criteria for SM are not 
fully met.3
Anaphylaxis is a well‐known feature of cMCD; particularly, 
venom allergy represents an increased risk of severe, even fatal, 
sting anaphylaxis in these patients.4,5 Although the overall prev‐
alence of Hymenoptera venom‐induced anaphylaxis (HVA) is ap‐
proximately 25% in patients with SM,6 the underlying reason(s) 
for this association remains elusive. The aggravated risk of severe 
HVA might be due to increased MC burden, perivascular aggre‐
gation of MCs and an amplified IgE reaction due to the presence 
of D816V KIT mutation.7 These findings stress the importance of 
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Abstract
Background: Patients with clonal mast cell disorders (cMCD), systemic mastocytosis 
(SM) and monoclonal mast cell activation syndrome (MMAS), represent an increased 
risk for Hymenoptera venom anaphylaxis (HVA). Lifelong venom immunotherapy 
(VIT) is recommended; however, its efficacy and safety are controversial. Hence, we 
sought to evaluate the efficacy and safety of VIT in HVA patients with cMCD.
Methods: A retrospective study was conducted among 46 patients with Vespula 
venom allergy who had experienced severe HVA, 32 cMCD (22 with SM and 10 with 
MMAS) and 14 controls. There were no differences between cMCD patients and 
controls in age (58 vs 66) and duration of VIT (47 vs 48 months), respectively.
Results: During VIT, 11 (34%) cMCD patients experienced adverse reactions (ARs) 
(7% in controls), including 1 anaphylaxis. There were 23 re‐stings in 17 (53%) patients 
during VIT. Of episodes, four (17%) presented with anaphylaxis, 14 (60%) presented 
with local reaction, and five (23%) were asymptomatic. In 11 episodes (48%), the 
patient did not take epinephrine, of these 8 (73%) presented with local reaction, and 
3 (27%) were asymptomatic. Patient‐based protection from anaphylaxis was 76% 
(4/17) in cMCD vs. 100% in controls during VIT. The venom‐specific IgG4 concentra‐
tions increased during VIT (P < .001) although tryptase and IgE were unaltered.
Conclusion: Both safety and efficacy of VIT in cMCD patients were slightly reduced 
than controls. Severe ARs were rare. The elevated IgG4 levels may be a biomarker 
for efficacy of VIT in cMCD patients, as it correlates with protection from re‐stings.
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accurate diagnostics; therefore, underlying cMCD should be con‐
sidered in patients with HVA that have elevated serum baseline 
tryptase	 levels	 (sBT)	 (≥11.4	 ng/mL).	 Additionally,	 sensitization	
against Hymenoptera venom components should be confirmed by 
skin prick test and/or serum‐specific IgE assays. However, it must 
be	noted	that	patients	with	cMCD	and	HVA	may	lack	sensitization	
to venoms.4,8
Venom immunotherapy (VIT) has been used for treatment of 
patients with diagnosed cMCD and HVA since 1990s; however, 
increased adverse reactions (ARs) and reduced efficacy have been 
main concerns in earlier studies.9 As many as 6 in 7 patients with 
cMCD had reactions to field re‐stings, despite ongoing VIT treat‐
ment.9 This raised concerns and controversies about current rec‐
ommendations regarding necessity and duration of VIT in patients 
with cMCD. Interestingly, more recent studies found VIT to be safe 
and effective in patients with cMCD but acknowledged a reduced 
efficacy and more frequent ARs during the administration of VIT 
compared with the general population.10‐13 At present, there is no 
evidence that VIT induces sustainable tolerance in patients with 
cMCD. Hence, the current recommendation is to proceed lifelong 
VIT in these patients.14 Additionally, the known markers of success‐
ful VIT (IgG4, IL‐10, regulatory T cells) have not been specifically 
studied in cMCD patients.
Thus, there is a continuing unmet need for further studies regard‐
ing VIT in patients with cMCD, as the available observations are based 
on limited number of reports. Here, we sought to determine the safety 
and efficacy of VIT by evaluating ARs during the administration of VIT 
and assessing the severity of field re‐sting reactions. Furthermore, we 
also analysed the efficacy by monitoring certain biomarkers before 
and during ongoing treatment in patients with cMCD.
2  | METHODS
2.1 | Patients and clinical procedures
Between January 2006 and December 2018, 396 consecutive adult 
patients	 (≥18	 years	 old)	 have	 been	 referred	 to	 the	 Mastocytosis	
Centre Karolinska due to clinically suspected cMCD including pa‐
tients with mastocytosis in the skin, patients with severe anaphylaxis 
or patients with elevated baseline tryptase levels of unknown origin. 
The final diagnoses, for example, SM or MMAS, were obtained after 
a comprehensive medical evaluation and bone marrow investigation 
following WHO criteria.3 Moreover, sBT levels (Thermo Fisher) were 
measured.
Anaphylactic reactions were diagnosed in accordance with 
NIH clinical criteria, when either reduced blood pressure or as‐
sociated symptoms such as syncope/presyncope and/or respira‐
tory compromise were present accompanied by the involvement 
of the skin‐mucosal tissue and/or gastrointestinal symptoms.15 In 
cases where assessments were difficult because of insufficient 
documentation, only patients who had syncope episodes after ex‐
posure to a likely trigger (eg insect sting) were assessed to have 
anaphylaxis. When available, serum tryptase levels during acute 
episodes were applied to confirm anaphylaxis. The diagnosis of 
HVA was based on clinical history, skin prick test and/or allergen‐
specific lgE.16
G R A P H I C A L  A B S T R A C T
Patients with clonal mast cell disorders (cMCD) convey increased risk for venom‐induced anaphylaxis and lifelong venom‐immunotherapy 
(VIT) is recommended, when appropriate. VIT appears to be rather safe and effective in cMCD patients, as the risk of severe adverse 
reactions are rare. Elevated levels of venom‐specific IgG4 correlates with protection from re‐sting anaphylaxis in cMCD patients during VIT.
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2.2 | Allergy work‐up
As previously described,4 all patients went through a complete al‐
lergic work‐up at Karolinska University Hospital Huddinge, allergy 
outpatient clinic including medical history, skin prick testing (SPT) 
with commercial extracts (ALK‐Abelló A/S, Horsholm, Denmark) of 
standard aeroallergens, food allergens and allergen of Hymenoptera 
venom (honeybee and common wasp). The venom‐specific lgE 
antibody test for honeybee and Vespula venom (ImmunoCAP 
Phadiatop®, Thermo Fisher, Uppsala, Sweden) was also performed 
and considered positive for values >0.10 kU/L. Moreover, serum 
concentrations of component‐specific venom lgE (Ves r5, Ves r1, 
Api m1 and Api m10); venom‐specific lgG4; and serum total lgE 
were determined by ImmunoCAP® (Thermo Fisher).
2.3 | Study design and subjects
A retrospective study was conducted. Data were collected through re‐
view of electronic patient records. Of 396 investigated patients, 178 had 
experienced at least one anaphylactic reaction (Figure 1). Among these, 
97 patients with HVA were identified. After excluding 51 patients, 46 pa‐
tients with Vespula venom allergy who fulfilled the criteria for VIT14 were 
enrolled in this study (Figure 1). Of study subjects, 32 had diagnoses of 
cMCD and HVA. Additionally, 14 patients with HVA and normal sBT lev‐
els (<11.4 ng/mL) were included as controls to compare the safety and 
efficacy of VIT. The study was approved by Stockholm's Ethics Review 
Board (Dnr: 2011/1750/31/3 and Dnr: 2018/2621‐31), and all enrolled 
patients provided their written informed consent to participate.
2.4 | Venom immunotherapy and follow‐up
Venom immunotherapy was started with Vespula extract (ALK‐
Abelló) according to a 7‐week traditional build‐up schedule at the al‐
lergy outpatient clinic. Patients received incremental, weekly doses 
of depot venom extract subcutaneously until a maintenance dose 
(1 mL of 100 000 SQ‐U/mL, corresponding to 100 µg) was reached. 
The achieved maintenance dose was then given every four (between 
May and October; high‐risk season) or 6 weeks (between November 
and April; low‐risk season for stings), and follow‐up ended on 31 
December 2018. All patients received premedication with HI block‐
ers, 1‐2 hours prior to VIT, and were observed 45 minutes after 
each injection. Extra drugs were given in case of acute reactions. 
Additionally,	 simultaneous	 treatment	 with	 omalizumab	 (Xolair®)	
during VIT was documented, when applied.
Blood samples were collected as part of routine patient care, and 
biological markers were in general analysed before VIT started and at 
different time points during VIT. Information about possible ARs was 
documented during the routine VIT visits, or as in few cases, patients 
reported late ARs by phone. Data about field re‐stings during VIT and 
their outcomes were documented at the time of next follow‐up visit 
and confirmed by the emergency room (ER) reports, when available.
2.5 | Statistical analysis
All analyses were performed using IBM SPSS Statistics 24.0 
(IBM). Values of P < 0.05 were considered statistically significant. 
Frequencies were reported for categorical variables, and group 
F I G U R E  1   The flow chart illustrates the selection process of the study subjects. *35 patients were excluded due to various reasons 
(15 received VIT at other clinics, 7 had elevated baseline tryptase levels without underlying cMCD, 6 declined to undergo VIT, 4 
had	comorbidities	with	cancer,	two	patients	were	investigated	during	study	start,	and	1	patient	was	sensitized	for	honeybee	only).	
Abbreviations: w/o, without; VIT, venom immunotherapy; MCD, mast cell disorders
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differences were analysed by using Fisher's exact test. Continuous 
variables were presented as median values and ranges. Because the 
distribution of the data was not normal according to Shapiro‐Wilk 
test, the nonparametric Mann‐Whitney U test or Kruskal‐Wallis test 
was used to compare the group distributions, when appropriate. 
Additionally, when crude data analysis was significant, a post hoc 
analysis was performed using the Wilcoxon's matched pair rank sum 
test to detect alterations at different time points within groups. We 
used Spearman's rank correlation coefficient to demonstrate clinical 
relevance of venom‐specific IgG4 during re‐stings. Since re‐stings 
were unpredictable, and it was impossible to assess the IgG4 on the 
day of re‐sting, we used IgG4 concentrations closest to the day of 
re‐sting occasions.
3  | RESULTS
3.1 | Patient characteristics and clinical data prior to 
venom immunotherapy
Of 32 patients with cMCD, 22 were diagnosed with indolent SM; 64% 
were males and had a median age of 61 (range 40‐80) at diagnosis. 
Additionally, 45% of patients with SM (10/22) had cutaneous involve‐
ment, 36% had MC clusters in  bone marrow biopsy, and 86% carried 
a KIT D816V mutation. They started VIT at a median age of 62 (40‐81) 
years and received the treatment for a median period of 45 months 
(7‐154). The remaining 10 cMCD patients were diagnosed with 
MMAS; 56% were males and had a median age of 55 (range 38‐71). 
All MMAS patients had MCs expressing CD25+ aberrant immunophe‐
notype, whereas 22% concomitantly carried a KIT D816V mutation. 
They started VIT at a median age of 52 (38‐66) years and received VIT 
for a median period of 77 months (9‐104). Bone marrow examinations 
were offered to all but performed only in 4 of 14 controls, since most 
refused to undertake the procedure. Additionally, peripheral blood 
KIT D816V mutation was negative in all analysed controls (n = 11).
Subjects with cMCD were more often males (63%) than in the con‐
trol group (43%), although this finding was not statistically significant 
(Table 1). Serum baseline tryptase levels were significantly higher in 
patients with cMCD, whereas total IgE were significantly higher in con‐
trols (Table 1). Moreover, controls presented with significantly higher 
levels of venom‐specific IgE and component rVes v5 (P = .001; Table 1). 
To note, 57% of patients in control group suffered from cardiovascular 
comorbidities including hypertension and/or angina pectoris prior to 
the culprit sting reaction (P < .001; Table 1). Regarding the severity 
of culprit reactions, both cMCD patients and controls presented with 
severe HVA, where syncope frequently occurred (82% of the patients 
with SM, 56% with MMAS patients and 57% in controls). Additionally, 
controls frequently presented with skin symptoms (P < .001); other‐
wise, there were no significant differences between the two groups in 
terms of reaction severity (Figure 2).
VIT started in subjects with cMCD at an earlier age with a me‐
dian of 58 years compared to 66 years in controls (Table 2). The du‐
ration of VIT was similar between the two groups and varied among 
individual patients due to the retrospective nature of the study. A 
total of seven patients discontinued VIT mainly due to the appear‐
ance of comorbidities (including cancer) or were referred to home 
clinics for practical reasons.
3.2 | Adverse reactions during VIT
Among patients with cMCD, 11 (34%) experienced ARs, eight (73%) 
during the induction phase and three (27%) during maintenance. The 
total number of episodes was 16, and epinephrine was administered 
twice (Table 2). Nine of these episodes were only local reactions, and 
six involved milder systemic reactions (without respiratory/cardio‐
vascular symptoms). Conversely, ARs in controls were limited to one 
patient (7%) who reacted with milder systemic reaction (Table 2). 
Anaphylaxis was observed only in one patient with SM who re‐
ceived simultaneous immunotherapy against wasp and honeybee 
and occurred nine months after the maintenance phase of VIT had 
started. The patient presented with flush and general weakness a 
TA B L E  1   Comparison of demographic, clinical and laboratory 
characteristics of cMCD patients with HVA compared to controls 
with HVA prior to VIT
Total, n = 46




(n = 14) P‐value
Male gender, n (%) 20/32 (63) 6/14 (43) .333a
Age at diagnosis, me‐
dian (range)
59 (38‐80) 66 (46‐78) .129b












Presence of atopy, n (%) 10/32 (31) 3/14 (21) .724a










































Syncope from wasp 
sting prior to VIT
24/32 (75) 8/14 (57) .301a
Comorbidity with CVD 
prior to first sting, 
n (%)
2/32 (6) 8/14 (57) <.001a
Abbreviations: cMCD, clonal mast cell disorders; CVD, cardiovascular 
disease; HVA, Hymenoptera venom anaphylaxis; NA, not analysed; ND, 
not done; sBT, serum baseline tryptase; SPT, skin prick test; VIT, venom 
immunotherapy.
aP‐values were calculated using Fisher's exact test; 
bP‐values were calculated using a 2‐tailed Mann‐Whitney U test; bold 
indicates statistical significance (P < .05). 
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few minutes after receiving both VIT injections. The blood pressure 
was initially normal (122/70 mm Hg). Despite receiving immediate 
treatment with epinephrine, 3‐4 minutes later the patient had docu‐
mented hypotension (80/44 mm Hg). He received another dose of 
epinephrine and intravenous fluid before he was transferred to the 
ER. Afterwards, VIT could be resumed, however, solely with wasp 
extract	 and	 in	 conjunction	 with	 omalizumab	 (Xolair@)	 treatment	
(300	mg	q2weeks).	The	omalizumab	treatment	has	been	continued,	
and	 no	 further	 incidences	 occurred	 since	 then.	 Omalizumab	 pro‐
tection was applied in two other patients (diagnosed with SM and 
MMAS, respectively), and the treatment was discontinued after 54 
and 20 months, respectively. Thereby, VIT was tolerated, as these 
patients	still	receive	VIT.	We	needed	to	apply	omalizumab	in	these	
patients to achieve maintenance doses since it has been reported in 
the literature with successful results to allow administration of VIT.
3.3 | Protection from re‐sting reactions while 
ongoing VIT
A total of 17 (53%) patients with cMCD were re‐stung in 23 separate ep‐
isodes. Epinephrine was used in 12 episodes. One sting occurred during 
the induction phase and the remaining during the maintenance phase. 
Six episodes were asymptomatic, 10 resulted in local reaction, and three 
resulted in milder systemic reactions. Four episodes (in four separate 
patients) were assessed to be anaphylactic reactions, and all four pa‐
tients used intramuscular epinephrine and sought emergency care 
(Table 3). Table S1 shows the main characteristics of 5 patients with ana‐
phylaxis during VIT (four anaphylaxis during re‐stings and one anaphy‐
laxis as AR). Interestingly, these five patients had positive SPT for wasp 
at baseline (Table S1), whereas only 22 patients in overall cohort (71%) 
(Table 1). Nevertheless, this was not clinically significant. Meanwhile, 
five (35%) controls were re‐stung in a total of eight episodes, which oc‐
curred during the maintenance phase of VIT (Table 3). Epinephrine was 
used in two episodes, although no anaphylaxis was observed.
During VIT, clinical symptoms from re‐stings were found to be less 
severe compared to culprit reactions. Most re‐sting reactions in pa‐
tients with cMCD were limited only to skin; moreover, 23% were as‐
ymptomatic. In contrast to the culprit reactions, where 75% of patients 
with cMCD had syncope, only one patient (5%) had syncope during 
re‐stings (P < .001). Consequently, we observed 76% (13/17) patient‐
based and 83% (19/23) episode‐based protection from anaphylaxis in 
patients with cMCD during field re‐sting reactions (P < .001).
F I G U R E  2   Clinical symptoms in 
patients with cMCD and controls during 
the culprit anaphylactic reactions to 
wasp sting prior to VIT. Statistical 
analysis performed by Fisher's exact 
test. *Hypotension, objectively verified. 
Abbreviations: F/U, faecal and/or urinary 
incontinence; GI, gastrointestinal cramps, 
nausea, vomiting and diarrhoea; RESP, 
respiratory symptoms; SKIN, local 





(n = 14) P‐value
Age at start of VIT, median (range) 58 (38‐81) 66 (45‐79) .127a
Total VIT duration (months), median (range) 47 (7‐154) 48 (13‐65) .277a
Patients with adverse reactions from VIT, n (%) 11/32 (34) 1/14 (7) .073b
Total number of episodes with adverse reactions (n) 16 1 ND
Mild systemic adverse reactions, n (%) 7/16 (44) 1/6 (17) ND
Patients with anaphylactic reaction from VIT, n (%) 1/32 (3) 0/6 (0) ND
Total number of injections, n 1 781 493 ND
Number of injections needed per adverse reaction, n 111 1 ND
Number of injections needed per anaphylaxis, n 1 781 ND ND
Use of adrenaline in adverse reaction, n (%) 2/16 (18) 0/1 (0) ND
Abbreviations: cMCD, clonal mast cell disorders; ND, not done; VIT, venom immunotherapy.
aP‐values were calculated using a two‐tailed Mann‐Whitney U test. 
bP‐value was calculated using Fisher's exact test. 
TA B L E  2   Group comparison of adverse 
reactions during VIT
174  |     JARKVIST eT Al.
3.4 | Dynamics of biomarkers in patients with 
cMCD during VIT
Serum concentration of wasp‐specific lgG4 increased significantly in 
patients with cMCD over the period of VIT (P < .001; Table S2). In con‐
trast, repeated measures of other biomarkers including plasma levels 
of sBT, total IgE, wasp venom‐specific IgE or venom component rVes 
v5 did not show significant dynamics during VIT compared to baseline 
levels. Calculation of specific ratios incorporating IgG4 did not pro‐
vide any additional significance beyond IgG4 levels alone (Figure S2).
On group level, the median of wasp‐specific lgG4 before VIT was 
0.52 mg/L (range 0.04‐8.9) in cMCD (Table S2). Two outliers were 
identified (2.4 and 8.9 mg/L, respectively) at baseline, and both 
previously completed a 5‐year VIT course (Figure 3A). Afterwards, 
VIT was restarted when both patients were diagnosed with cMCD. 
We also evaluated wasp‐specific IgG4 levels in six cMCD patients 
in relation to nine re‐sting reactions and found an inverse correla‐
tion between IgG4 concentrations and reaction severity (P < .01; 
Figure 3B). Since IgG4 could not be obtained on the day of the 
re‐stings, we analysed the closest IgG4 values in relation to day of 
reactions (median 4 months, range 0‐10). Two patients who were as‐
ymptomatic in three episodes when re‐stung had wasp‐specific IgG4 
levels between 21 and 25 mg/L. Conversely, the only patient who 
reacted in two episodes during the same summer with mild systemic 
reactions presented with lower wasp‐specific IgG4 levels, 10 and 
11 mg/L prior to and after the stings. The remaining five patients 
who only experienced local reactions (<10 cm in diameter) had IgG4 
concentrations between 8 and 21 mg/L.
4  | DISCUSSION
Our results support that VIT appears to be rather safe and effective 
in patients with cMCD and HVA as the risk of severe systemic ARs 
was rare. Additionally, significantly increased serum concentrations 
of wasp‐specific IgG4 were detected; this is, to our knowledge, the 
first report demonstrating this phenomenon in cMCD patients.
While allergic reactions to foods and drugs have been reported 
in cMCD, the primary trigger for IgE‐mediated severe, even fatal, 
anaphylactic reactions remains Hymenoptera stings.17,18 In general, VIT 
induces protection from severe sting reactions in HVA patients during 
and after discontinuation of therapy.19‐22 Nevertheless, there have 
been controversies regarding its safety and efficacy in patients with 
cMCD. ARs to VIT have been reported in 29% of patients with cMCD 
compared to 14% in general HVA population.12,23 VIT protocols applied 
during induction phase are also essential since increased frequencies 
of ARs were reported in rush‐ or ultrarush protocols.24 Interestingly, 
no ARs were observed in a recent study of eight mastocytosis patients 
receiving VIT by ultrarush protocol.25 Our study supports previous 
findings as we found a fivefold increased risk for ARs in cMCD patients 
compared to controls (34% vs 7%, respectively). Additionally, the ARs 
occurred mainly during the build‐up phase, of which 44% were milder 
systemic reactions. Only one patient suffered from an anaphylactic re‐
action (3%). Of note, this patient was treated with both honeybee and 
wasp venom simultaneously, a procedure reported to increase the risk 
of ARs.12 No patients in the current study had to be discontinued; how‐
ever, VIT in patients with cMCD is not risk‐free.
Efficacy of VIT is typically evaluated by sting challenges and 
reports from field re‐stings; however, sting challenges are not per‐
formed in all clinics.14 Several studies have reported on efficacy as 
the rate of protection from systemic reactions; nevertheless, no uni‐
versally accepted grading system exists to classify the severity of 
systemic reactions.26 This complicates comparison of the efficacy 
of VIT across different studies.27 In patients with mastocytosis, the 
protection rate varied from 14% to 85% in a review of 10 studies with 
201 patients.12 Our results support VIT being an efficient treatment 
to prevent anaphylaxis, since only four episodes (17%) from field re‐
stings were classified as anaphylaxis. That implies a protection rate 
of 83%, in line with a previous report (86%).10 Only one patient with 
cMCD reacted with syncope when re‐stung compared to 75% during 
culprit reactions (P < .001). There were no fatalities in our series. 
However, since this protection can only be sustained during VIT, the 
current guidelines recommend lifelong VIT in patients with cMCD.
Notably, the severity of culprit reactions in patients with 
cMCD appears to be independent from concomitant cardiovascu‐
lar diseases (CVDs) and use of beta blockers and/or ACE inhibitors 
since the control subjects more frequently presented with CVDs 





(n = 14) P‐value
Patients who were re‐stung during VIT, n (%) 17/32 (53) 5/14 (35) .346
Number of patients with anaphylactic reaction, n (%) 4/17 (24) 0 (0) ND
Protection from anaphylaxis per subject, n (%) 13/17 (76) 0/5 (100) ND
Number of episodes of re‐stings (n) 23 8 ND
Episodes with anaphylactic reaction to re‐sting, n (%) 4/23 (17) 0/8 (0) ND
Protection from anaphylaxis per episode, n (%) 19/23 (83) 8/8 (100) ND
Use of adrenaline in episode of re‐sting, n (%) 12/23 (52) 1/8 (13) .095
Abbreviations: cMCD, clonal mast cell disorder; ND, not done; VIT, venom immunotherapy.
P‐values were calculated using Fisher's exact test.
TA B L E  3   Comparison of patients with 
cMCD and control subjects regarding re‐
sting reactions during VIT
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mechanisms leading to severe HVA in cMCD patients may be dif‐
ferent from those of controls; for instance, they might be due to the 
inherent mast cell hyperreactivity. Additionally, the serum concen‐
tration of the venom‐specific IgE and component‐specific venom IgE 
rVes v5 (which is the dominating allergic epitope in Sweden) levels 
at baseline was lower in patients with cMCD compared to controls 
(P = .013). It is known that patients with SM typically exhibit lower 
levels of total and specific IgE, presumably due to the adsorption of 
specific IgE by the expanded MC burden28; however, whether this is 
true also for rVes v5 has not been previously investigated.
The immunological mechanisms underlying VIT efficacy have not 
been fully elucidated, although induction of peripheral tolerance and 
the generation of allergen‐specific regulatory T (Treg) and B (Breg) cells 
appear	to	be	cardinal	features.	Treg	cells	are	characterized	by	IL‐10	se‐
cretion that directly or indirectly suppresses effector cells including 
mast cells, and also have influence on B cells, suppressing IgE produc‐
tion and inducing the production of blocking‐type IgG4 antibodies 
against venom allergens.29‐33 The earlier studies concerned patients 
from the general HVA population and acknowledged that specific IgG 
levels increased significantly during VIT but also decreased signifi‐
cantly when VIT was discontinued.21,34‐36 Since a protective effect was 
still evident even after VIT was discontinued, they concluded other im‐
munological mechanisms rather than specific IgG were likely responsi‐
ble. Nevertheless, these studies did not involve the IgG subclass, IgG4. 
Interestingly, another investigation reported that specific honeybee 
IgG4 concentrations remained increased two years after discontinuing 
VIT against honeybee, suggesting a long‐lasting protection of specific 
IgG4.37 This issue has been re‐evaluated in a recent study in patients 
with HVA and demonstrated increased levels of wasp‐specific IgG4 
during VIT course, but concentrations declined substantially at 3‐ and 
8‐year follow‐up after discontinuation of VIT.38 Additionally, Golden 
et al21 found that 88% of patients who reacted systemically to a sting 
during	VIT	had	venom‐specific	IgG	antibody	levels	≤3	mg/L,	thereby	
recommended that monitoring sIgG levels during VIT might be pre‐
dicting residual risk of systemic reactions after a sting. Similarly, a later 
study reported that monitoring VIT efficacy was only possible in ves‐
pid‐venom allergy, and the authors proposed that sIgG4 threshold for 
rVes v5 had the highest sensitivity to confirm tolerance.39
Currently, no studies have demonstrated sustained tolerance 
development in patients with cMCD. Because severe or fatal ana‐
phylactic reactions with re‐stings occur only in patients with cMCD 
after discontinuation of VIT, the immunological mechanism behind 
clinical efficacy may differ from nonclonal population.12,14 However, 
the dynamic of IgG4 during VIT has never been analysed in patients 
with cMCD. We demonstrated that venom‐specific IgG4 levels con‐
stantly increased during VIT and reached a 20‐fold increase during 
the first 2 years of treatment (Figure 3A). Additionally, when we ob‐
served wasp‐specific IgG4 in relation to re‐sting reactions, we found 
an inverse correlation between IgG4 levels and reaction severity sug‐
gesting that IgG4 concentrations might reflect the clinical efficacy 
(Figure 3B). Furthermore, we also identified two patients who had 
anaphylaxis when re‐stung, 4 and 11 years after having discontinued 
VIT. Both patients were later diagnosed with cMCD. The serum con‐
centrations of wasp‐specific IgG4 were clearly reduced in both (8.9 
and 0.72 mg/L, respectively) before VIT was restarted compared to 
patients with cMCD who had been continued VIT (median IgG4 con‐
centration 20.5 mg/L at years 5‐6). Hence, treatment failure may be 
related to inadequate levels of IgG4. VIT could be administered more 
frequently in these patients to attempt to raise the serum concentra‐
tion of venom‐specific IgG4, thereby increasing efficacy.
Conversely, no significant alterations during different time 
points of VIT were observed regarding the levels of tryptase, total 
IgE, wasp venom‐specific IgE and component‐specific venom IgE. 
Notably, previous studies demonstrated both decreased and un‐
changed levels of venom‐specific IgE during VIT.23,40,41 In the study 
by	Gonzales	et	al23 with SM patients and HVA, venom‐specific IgE 
F I G U R E  3   A, Dynamic of wasp‐specific IgG4 levels in cMCD 
patients during VIT. Two outliers were identified (2.4 and 8.9 mg/L, 
respectively) at baseline, and both patients previously received 
VIT. P‐values were analysed with Wilcoxon's matched pair rank 
sum test. A significant increase was noted between baseline and 
years 1‐2 (P = .028) and between years 3‐4 and years 5‐6 (P = .018). 
n; number of matched patients at different time points. Different 
colours represent different time periods. B, Correlation between 
wasp‐specific IgG4 levels and severity of re‐sting reaction. The 
reactions were classified as asymptomatic, local reactions (<10 cm 
in diameter) and mild systemic reactions (without respiratory 
or circulatory compromise). Correlation was quantified by using 
Spearman's rank correlation coefficient
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levels decreased for the entire group during VIT. However, only 6 of 
21 patients had Vespula venom allergy.23 Remarkably, their patients 
had relatively high median levels of specific IgE before VIT compared 
to our patients (4.15 KU/L vs 0.54kU/L). These might be contributing 
to the contradictory results. Meanwhile, tryptase levels remained 
unchanged during VIT in both studies.23
The main strength of this single‐centre study was the homo‐
geneity of the subjects enrolled, since all patients received VIT 
against wasp, with extract from the same manufacturer and fol‐
lowed by similar VIT protocols. We could therefore compare pa‐
tients with cMCD to control patients in the same clinical settings. 
By contrast, paucity of study subjects and retrospective nature of 
the study lacking relevant data from all patients at all time points 
analysed	 were	 our	 limitations	 making	 difficult	 to	 generalize	 re‐
sults. When reactions to re‐stings were assessed, patient‐reported 
data were unavoidably used and could include a recall bias. Use 
of epinephrine is a confounding factor that could not be avoided. 
Finally, several symptoms from systemic allergic reactions and 
panic attacks overlap, for example anxiety and tachycardia, and all 
these factors complicate clinicians' assessment of reactions.
In conclusion, our results suggest that both efficacy and safety 
of VIT are somewhat less reliable in cMCD patients, but the over‐
whelming benefit justifies the relatively small increase in risk, as 
severe ARs are rare. The patient‐based and episode‐based protec‐
tive rate from field re‐sting anaphylaxis were 76% and 83%, respec‐
tively; nevertheless, the efficacy of treatment was only measured 
during VIT course. Therefore, we support the notion that patients 
with cMCD should continue VIT indefinitely. Over the course of VIT, 
venom‐specific IgG4 antibodies were increased significantly in pa‐
tients with cMCD and an inverse correlation between IgG4 levels 
and reaction severity to field re‐stings appears to exist. Using wasp‐
specific IgG4 to monitor clinical efficacy may allow us to schedule 
more	individualized	administration	of	VIT;	however,	this	issue	needs	
to be further explored.
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